[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurogenic-bladder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurogenic-bladder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,45,73,100,138,163,191,214,237,277,298,332,355,377,404,427],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643857","phase-1-device-for-bladder-control-for-men-with-sci-100643857",false,"NCT07668063","Device for Bladder Control for Men With SCI","Noninvasive Electrical Stimulation Device to Improve Bladder Control for Men With Spinal Core Injury","Inclusion Criteria:\n\n* Suprasacral SCI\n* Neurologically stable\n* Skeletally mature\n* Presence of reflex bladder contractions\n* At least 12 months post SCI\n\nExclusion Criteria:\n\n* Active sepsis\n* Open pressure sores on or around pelvis\n* Bleeding diathesis\n* Significant urethral trauma, erosion, or stricture\n* Indwelling catheter for over 1 year AND bladder capacity less than 100 mL\n* Significant history of autonomic dysreflexia","MALE","18 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Urinary incontinence, bladder frequency, and bladder urgency are significant medical problems for people with overactive bladder (OAB) or neurogenic bladder overactivity (NDO). Affected individuals typically experience reflex bladder contractions in response to bladder filling at low volumes, resulting in urinary incontinence and decreased bladder capacity. This project will advance a new device for administering noninvasive electrical stimulation in order to improve bladder control.",[27],"Neurogenic Bladder",[29,30,31],"Neurogenic detrusor overactivity","Spinal cord injury","Genital nerve stimulation","NOT_YET_RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":20},"2028-06-01",{"date":40,"type":20},"2029-12-31",{"name":42,"class":43},"VA Office of Research and Development","FED",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100528645","effect-of-chlorhexidine-gluconate-bladder-instillations-in-patients-with-chronic-suprapubic-catheters-on-unplanned-healthcare-encounters-and-quality-of-life-100528645","NCT06163469","Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life","Instillation in Neurogenic Bladders to Decrease Unplanned Healthcare Encounters","Inclusion Criteria:\n\n* Indwelling suprapubic catheter with insertion date at least 1 year prior to study enrollment date.\n* History of urinary tract infections, treated for at least 1 positive urine culture in last 6 months\n\nExclusion Criteria:\n\n* Current radiographic evidence of urolithiasis\n* History of vesicoureteral reflux\n* History of renal transplantation\n* History of bladder augmentation\n* Inability to stop use of other rUTI prophylaxis treatments for the duration of their trial enrollment\n* Life expectancy of less than 12 months prior to consent.\n* Known hypersensitivity or allergy to chlorhexidine.\n* Women who are pregnant or breastfeeding.","ALL",{"count":54,"type":20},70,[56],"NA","The goal of this clinical trial is to evaluate the feasibility and tolerability of 0.05% Chlorhexidine Gluconate (CGH) bladder instillations in an outpatient setting at the time of suprapubic catheter (SPC) exchange in patients with history of recurrent urinary tract infections (UTI). The main questions are:\n\n1. is instillation of 150mL of CGH for five-minute duration at the time of SPC exchange feasible in an outpatient setting and tolerable for patients.\n2. does this protocol decrease the rate of unplanned health care visits and improve patient quality of life.\n\nPatients will undergo the treatment protocol during their routine suprapubic catheter exchanges.",[27,59],"Urinary Retention",[61,62],"recurrent UTI","bladder irrigation","RECRUITING","2026-06-17",{"date":33,"type":36},{"date":67,"type":36},"2024-04-01",{"date":69,"type":20},"2027-12-31",{"name":71,"class":72},"Yale University","OTHER",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":44},"100423263","phase-2-antibiotic-prophylaxis-for-neurogenic-bladder-botox-100423263","NCT04791579","Antibiotic Prophylaxis for Neurogenic Bladder Botox","Prophylactic Antibiotics Following Treatment of Neurogenic Overactive Bladder With Intradetrusor onabotulinumtoxinA for the Reduction of Postoperative UTI: a Randomized Blinded Placebo-controlled Trial","Inclusion Criteria:\n\n1. Participants with neurogenic OAB, defined as OAB associated with a neurologic condition such as multiple sclerosis, Parkinson's disease, spinal cord injury, previous stroke, or any other neurologic condition the participant may have been told is a cause of their OAB symptoms\n2. Age ≥ 18\n3. Participants must be able to read, speak, and write in English\n4. No contraindication to injection of Botox - hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation, symptomatic urinary retention or PVR \\> 200 mL, unwillingness or inability to initiate CIC post-treatment if required.\n5. No contraindication to oral Ciprofloxacin - hypersensitivity or allergy to Ciprofloxacin or other fluoroquinolone, concurrently taking Tizanidine or Agomelatine.\n6. No active antibiotic therapy for any indication at the time of Botox injection\n7. Not pregnant and\u002For breastfeeding - Botox is contraindicated in pregnancy (screen serum pregnancy test 72 hrs prior to the procedure is standard of care).\n8. No active symptomatic UTI the day of the procedure - wherein the participant presents the day of their Botox procedure with new or worsening urinary frequency, urgency, dysuria, hematuria, suprapubic\u002Fflank pain, fevers or chills, will be ground for exclusion from the study - bladder Botox is contraindicated in patients with active symptomatic UTI\n\nExclusion Criteria:\n\n1. Participants with idiopathic OAB\n2. Age \\\u003C 18\n3. Patients who cannot read, speak, and write in English\n4. Any contraindication to injection of Botox - hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation, symptomatic urinary retention or PVR \\> 200 mL, unwillingness or inability to initiate CIC post-treatment if required.\n5. Any contraindication to oral Ciprofloxacin - hypersensitivity or allergy to Ciprofloxacin or other fluoroquinolone, concurrently taking Tizanidine or Agomelatine.\n6. Active antibiotic therapy for any indication at the time of Botox injection\n7. Pregnant (as indicated by pre-operative serum quantitative B-hCG for patients aged 18 to 51 without previous hysterectomy) and\u002For breastfeeding\n8. Active symptomatic UTI the day of the procedure - wherein the participant presents with new or worsening frequency, urgency, dysuria, hematuria, suprapubic\u002Fflank pain, fevers or chills, will be ground for exclusion from the study.","100 Years",{"count":82,"type":20},160,[24],"Injection of Botox into the bladder is a procedure used to treat neurogenic overactive bladder at the Dianne and Irving Kipnes Urology Centre in the Kaye Edmonton Clinic. A common complication following bladder Botox is bladder infection. There are no well-studied preventative antibiotics given at the time of bladder Botox for the reduction of post-operative bladder infection. We are proposing a research study that will randomize participants into two groups - one receiving antibiotics and the other receiving placebo pills following bladder Botox. The main goal of our study is to determine if preventative antibiotics at the time of bladder Botox injection reduces post-operative bladder infection. It will provide a valuable learning opportunity for a trainee starting their academic career through working closely with established researchers across two disciplines. We hope the results of our study can ultimately be used to improve outcomes and safety for a common Urologic procedure. In addition, findings from our study could help reduce unnecessary use of antibiotics resulting in cost savings in the health care system and reduction in the risk of antibiotic resistance.",[27,86],"Post-operative Urinary Tract Infections",[88,89,90],"prophylaxis","post-operative infection","Botox","2026-05-05",{"date":93,"type":36},"2026-05-07",{"date":95,"type":36},"2025-02-01",{"date":97,"type":20},"2027-08-31",{"name":99,"class":72},"University of Alberta",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":52,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":112,"conditions":113,"keywords":122,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100410565","early-phase-1-concomitant-renal-and-urinary-bladder-allograft-transplantation-100410565","NCT04626167","Concomitant Renal and Urinary Bladder Allograft Transplantation","Inclusion Criteria:\n\n* Male or female patients between 1 yr. and 60 years of age.\n* Subject is willing and able to give signed informed consent, or have a legally authorized representative who is willing and able to give consent. Informed assent will be required for children 6-17 years of age as appropriate or warranted.\n* Patients with CKD secondary to neurogenic bladder, lower urinary tract obstruction or other disorders of the urinary bladder.\n* Medical need for a bladder transplant, as defined by the presence of exhibiting \"hostile bladders\" defined as end filling pressure or detrusor leak point pressure (DLPP) of or greater than 40 cm H20 or at below estimated bladder capacity for age, or detrusor overactivity with detrusor sphincter dyssynergia, or new onset of upper urinary tract changes (hydronephrosis, vesicoureteral reflux) in the last 12 months\n* If a concomitant kidney transplant is being considered, additionally, estimated GFR less than or equal to 20 mL\u002Fmin or dialysis. If GFR 20-25 mL\u002Fmin would also qualify if expected progression is rapid (\\>10 mL\u002Fmin\u002Fyear)\n* Vetting and approval by the Mayo Clinic multidisciplinary transplant team (MDC) for renal transplantation.\n* Ability of subject and\u002For care provider to be successfully trained in clean intermittent catheterization and bladder cycling. Or current use of CIC.\n* Utilization of maximally-tolerated dose and regimen of medical therapy (e.g. anticholinergics) or failure to tolerate\u002Fcontraindications to such agents.\n* Psychosocial clearance: Demonstrated commitment to psychological evaluation perioperatively, in which the psychologist must confirm that the subject has the maturity and stable psychosocial environment necessary for this research study.\n* Agree to avoid pregnancy for 1 year after surgery through abstinence or approved contraception as noted in Appendix A (female subjects only)\n* If patient has a history of malignancy (with the exception of localized non-melanoma skin cancer) the patient must be at least 5 years from termination of treatment without evidence of recurrent disease.\n\nExclusion Criteria:\n\n* They are pregnant or breastfeeding, or planning a pregnancy during the course of the study, or who are of child bearing potential and not willing to continue using an effective method of birth control (i.e. with a low failure rate of less than 1 percent per year including injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or a vasectomized partner), or\n* Any contraindication to general anesthesia or evaluation reveals that the subject cannot safely undergo general anesthesia and post-operative recovery due to severe cardiovascular, pulmonary, neurological, metabolic, or rheumatologic disease (requires special consultation)\n* Any contraindication or known anaphylactic or severe systemic reaction to either human blood products or materials of bovine origin\n* Subjects with a current positive (\\>=5 mm induration for high-risk subjects; otherwise \\>=10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n* Known history of hypersensitivity to aminoglycosides or fluoroquinolones\n* Use of any investigational product within 3 months\n* Prior participation in the study\n* Currently smoking\n* Current incarceration for any reason\n* Unwillingness, inability, or unlikely compliance of individual and\u002For primary caregiver with study related schedules procedures, management, or follow -up in the opinion of the PI and\u002For co-investigators\n* Any circumstance in which the investigator deems participation in the study is not in the subject's best interest\n* Subjects with an ALT or AST value \\>3 times the upper limit of normal\n* Subjects with acute or chronic abdominal skin infections and\u002For acute or chronic abdominal inflammatory conditions such as inflammatory bowel disease\n* Subjects with uncontrolled diabetes defined as HgA1c\\>10, unstable cardiac and\u002For pulmonary disorders, or bleeding disorders\n* Active malignant neoplasm (with the exception of localized non-melanoma skin cancer) that is untreated, unresponsive to available treatment, or too recently treated to determine relapse risk.\n* Surgical procedure for transplantation cannot be successfully performed for anatomical reasons\n* Life expectancy with successful transplantation is estimated to be \\\u003C5 years for any reason.\n* There is any other disease, physical examination finding, or clinical laboratory result that provides a reasonable suspicion of a disease or condition that contraindicates the procedure or the interpretation of results or render the subject at high risk for treatment complications, or\n* Serious or uncontrolled psychiatric illness or disorder that could compromise their understanding of, or compliance with, follow-up visits\u002Fcare after transplant, or\n* Taking medications on specified hourly intervals that may be affected by changes to renal clearance, or\n* Hypertension stage II \\> 99th percentile, unless they had a complete workup to exclude secondary etiologies other than being overweight, or\n* Presence of severe coagulopathy, (hyper or hypo)\n* Patient is not up to date on current CDC recommended vaccines","1 Year","60 Years",{"count":109,"type":20},30,[111],"EARLY_PHASE1","The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.",[114,115,116,117,27,118,119,120,121],"Chronic Kidney Diseases","Bladder Dysfunction","Bladder Absence","Posterior Urethral Valve","Bladder Exstrophy","Bladder Outlet Obstruction","Failure, Kidney","Transplant",[123,124,125,126,127],"Urinary Bladder Transplant","Bladder Transplant","Bladder Augment","Neobladder","Ileocystoplasty","2026-04-20",{"date":130,"type":36},"2026-04-23",{"date":132,"type":36},"2021-06-01",{"date":134,"type":20},"2026-08",{"name":136,"class":72},"Mayo Clinic",2,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":52,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":44},"100631842","bilateral-comparison-of-unilateral-sacral-neuromodulation-test-stimulation-in-the-treatment-of-neurogenic-bladder-100631842","NCT07505940","Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder","Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder: A Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. age ≥16 years old;\n2. The nerve injury was incomplete injury below grade B, which was diagnosed as neurogenic bladder;\n3. Overactive bladder with and\u002For low compliance bladder (overactive bladder was defined as detrusor contraction during filling, increased intravesical pressure, and early emptying before maximum bladder capacity was reached; Low compliance bladder was defined as loss of the ability to relax during bladder filling, progressive increase of bladder pressure, early emptying of bladder pressure increased, ≤20ml\u002FcmH20).\n4. Intermittent catheterization (CIC) can be performed by themselves or CIC can be performed by nursing staff;\n5. the patient's physical condition is stable and can be discharged for treatment;\n6. Participants voluntarily participated in the clinical study, and they provided written informed consent before the study began\n\nExclusion Criteria:\n\n1. Patients can not perform intermittent catheterization (CIC) by themselves and there is no nursing staff to perform CIC;\n2. a history of progressive neurological disorders;\n3. abnormal autonomic reflexes;\n4. pregnant, lactating women, women of childbearing age who plan to become pregnant during the study period, or who do not use safe contraception;\n5. patients with mental and cognitive impairment who are unable to cooperate with surgery and programming;\n6. patients have coagulopathy or need anticoagulant therapy and cannot stop the treatment;\n7. any serious complications or illnesses that may prevent the patient from participating in or increase the patient's risk of undergoing a surgical procedure;\n8. Participants who participated in other clinical trials within 3 months before screening, which may have affected the study results;\n9. other conditions considered by the investigator to be inappropriate for study participation.","16 Years",{"count":147,"type":20},29,[56],"Neurogenic bladder (NB) is a general term for a series of lower urinary tract symptoms and complications caused by bladder and\u002For urethral dysfunction caused by nervous system lesions. Neurogenic bladder brings physical and psychological pain to patients, affects interpersonal relationships, and seriously reduces the quality of life of patients.\n\nSacral neuromodulation (SNM) is an effective method for the treatment of refractory lower urinary tract dysfunction. A previous study analyzed bilateral peripheral nerve evaluation (PNE) in 62 patients with idiopathic and neurogenic bladder. The results of this clinical study showed that 51.6% of the patients (32 cases) achieved symptomatic improvement. Although a prospective controlled study was not performed, the authors suggest that bilateral treatment may improve symptoms in patients with idiopathic and neurogenic bladder compared with unilateral treatment, compared with remission rates in other previous clinical studies.\n\nAt present, there are few reports on the application of bilateral sacral neuromodulation stimulation in the treatment of voiding dysfunction, and it is still controversial whether the efficacy of bilateral stimulation is better than unilateral stimulation. Therefore, we intend to conduct a prospective, randomized controlled trial to evaluate the efficacy and safety of bilateral sacral neuromodulation test stimulation in the treatment of neurogenic lower urinary tract dysfunction.",[27],[152,153],"neurogenic bladder","sacral neuromodulation","2026-03-29",{"date":156,"type":36},"2026-04-01",{"date":158,"type":20},"2026-03-31",{"date":160,"type":20},"2027-03-01",{"name":162,"class":72},"Qilu Hospital of Shandong University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":171,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":189,"locationsCount":44},"100521677","neuromodulating-cortical-regions-involved-in-neurogenic-bladder-in-ms-100521677","NCT06072703","Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS","A Randomized, Sham-Controlled Clinical Trial Evaluating Individualized Neuromodulation of Cortical Regions Involved in Neurogenic Overactive Bladder in Multiple Sclerosis","MSBLADDER","Inclusion Criteria:\n\n* Adult women (≥ 18 years of age)\n* Clinically stable MS defined as ExpandedDisability Status Score (EDSS) ≤ 7.5without exacerbation worsening in the preceding 6 months prior to study entry\n* Neurogenic Lower Urinary Tract Dysfunction symptoms ≥ 3 months with NBSS total ≥ 15\n* Individuals with Montreal Cognitive Assessment (MoCA) score \\>10 will be eligible\n* At least one bladder storage symptoms (e.g., urinary frequency, urinary urgency, nocturia with or without incontinence) indicated by OAB -AT≥ 8\n* Individuals with active urinary tract infection (UTI) will be treated and will be enrolled after negative urinalysis\n\nExclusion Criteria:\n\n* Pregnant\u002Fplanning to become pregnant or nursing\n* Urodynamic findings of bladder outlet obstruction\n* Baclofen or other intrathecal pumps, Pacemakers.\n* History of seizure disorder (SZ), immediate family of SZ disorder, in addition to individuals who are taking any medications such as (bupropion) Wellbutrin or substances (ex: heavy alcohol use) that would lower seizure threshold will be excluded.\n* History of bipolar disorder, or individuals who are taking medications that can exacerbate the condition such as tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-nor-epinephrine reuptake inhibitors, anti-psychotics, lithium, bupropion (Wellbutrin) and antihistamines will be excluded.\n* All intracranial lesions and hemorrhagic stroke will be excluded\n* History of moderate to severe heart disease or unstable angina\n* History of Autonomic Dysreflexia\n* History of interstitial cystitis, pelvic radiation\n* Intra-detrusor botulinumtoxinA (BTX-A) injection over the past 6 months\n* Incarcerated patients will be excluded.\n* Active sacral nerve stimulation (SNS) device or any other spinal stimulators\n* Indwelling urethral or suprapubic catheter","FEMALE",{"count":147,"type":20},[56],"Neurogenic overactive bladder (NOAB), characterized by urinary frequency, urgency or urgency incontinence symptoms occurring during the storage phase of the bladder, is the most common urinary complaint in multiple sclerosis (MS). Current management options for NOAB in MS have limited efficacy and considerable adverse effects, which underscores the significance of this study and highlights the need for better, less invasive therapies. This novel study investigates brain therapeutic targets that could shift the focus of NOAB management in MS from a bladder-centric focus to brain restoration; specifically modulating the brain regions identified in the prior functional magnetic resonance imagining studies. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation that can modulate neurons (excite or inhibit) to improve the connectivity of the regions of interest (ROI). The preliminary data demonstrate, for the first time, significant improvement in bladder symptoms in ten women with MS who have voiding dysfunction following multifocal transcranial magnetic stimulation without any treatment-related adverse effects.\n\nThis randomized double-blind, sham-controlled single center clinical trial with an optional open-label extension (OLE) phase is designed to evaluate the effects of targeted rTMS in women with MS and NOAB by investigating restorative reorganization of brain function The main purpose of this study is to determine the effects of individualized repetitive Transcranial Magnetic Stimulation (rTMS) for improving overactive bladder symptoms such as urinary frequency and urgency with or without incontinence in individuals with multiple sclerosis (MS). Patients will undergo initial screening that includes a demographics information, physical exam, past medical and surgical history, medication list, urine pregnancy test (female subjects with childbearing potential), and completion of questionnaires to confirm the eligibility of patients. All eligible patients will be required to complete a functional MRI scan followed by locating the regions of interest through neural navigation system and finally receiving 10 treatment sessions.\n\nSince this is a randomized trial, some patients will receive active treatment\u002F therapy sessions while others will only receive sham or placebo treatments. The total duration to complete all treatment sessions and follow up visits is approximately 4-5 months.",[27,176,177],"Multiple Sclerosis","Overactive Bladder",[179,180,181,182],"Neurogenic bladder","Functional Neuroimaging","repetitive Transcranial Magnetic Stimulation (rTMS)","Neuromodulation","2026-03-18",{"date":185,"type":36},"2026-03-23",{"date":187,"type":36},"2023-10-30",{"date":69,"type":20},{"name":190,"class":72},"The Methodist Hospital Research Institute",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":201,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":44},"100561272","phase-3-assess-the-efficacy-of-om-89-vs-placebo-in-reducing-antibiotic-consumption-associated-with-the-treatment-of-urinary-tract-infections-in-patients-with-neurogenic-bladder-100561272","NCT06588010","Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder","Multicentre Randomised Double-blind Superiority Trial With a Roll-over Phase to Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder","RETRAIN","Inclusion Criteria:\n\n* Person who has given written consent\n* Patient aged 18 years or older\n* Patient with a stabilised neurogenic bladder following spinal cord injury thaht has not progressed for more than 2 years and who has undergone a urodynamic examination in the last 2 years.\n* Patients using CIC (5 to 6 per day)\n* Patients who have received at least 6 courses of antibiotic treatment for UTIs in the 12 months prior to screening (whether for curative or prophylactic reasons)\n* Patients with a negative urine culture between screening visit and randomisation or treated with antibiotics for urinary decontamination prior to randomisation.\n\nExclusion Criteria:\n\n* Person who is not affiliated with the national health insurance system\n* Person subject to a measure of legal protection (guardianship, tutorship)\n* Person subject to a court order\n* Adults unable to express consent\n* Patients using a urinary drainage method other than CIC\n* Patients with urinary lithiasis at the time of inclusion (assessed by renal imaging in the previous year as part of routine management for patients with a history(s) of lithiasis or within 3 years for patients with no history)\n* Presence of an endo-urinary device (urinary prosthesis, ureteral stent)\n* Enterocystoplasty or irradiated bladder (past or present)\n* Known allergy or previous intolerance to the active substance or one of the excipients of OM-89 or placebo\n* Patient requiring ongoing or short-term prolonged antibiotic therapy (e.g. infected bedsore, etc.)\n* Patient treated with bacterial lysates (including OM-89) in the 6 months prior to randomisation\n* Unable or unwilling to stop prophylactic antibiotic therapy prior to randomisation\n* Patient with a known malignant tumour or neoplasia\n* Patient with an autoimmune disease\n* Patient treated with long-term or bolus corticosteroids, anti-CD20 and anti-rejection therapy in the 6 months prior to screening\n* Patient currently taking part in another study on an investigational device or drug related to urinary tract infections, or who has received another investigational treatment in the 30 days prior to screening.\n* Patient unable to collect information in a daily diary.\n* Patient unable to understand follow-up by telephone.\n* Patients planning to move to another residence in the year following randomisation\n* Non-menopausal women who are not surgically sterile (bilateral oophorectomy or hysterectomy) AND pregnant, breast-feeding who are declare that they are planning to conceive at inclusion, or not using effective\\* contraception.",{"count":200,"type":20},110,[202],"PHASE3","Recurrent urinary tract infections (UTIs) in patients with a neurogenic bladder using clean intermittent catheterization (CIC) are a major problem. In this population, urinary tract infections are the most frequent cause of morbidity and the second leading cause of mortality (Buzzell A, Spinal Cord, 2020). It is also the leading cause of healthcare use and consumption (A. Dinh, MMI 2019). In addition, multidrug-resistant bacteria (MRB) are frequently implicated, accounting for up to 50% of cases (Samal V BMC Infect Dis 2022, A. Dinh Spnal cord 2016), due to high exposure to antibiotics and frequent and prolonged hospitalisations.\n\nThe very frequent recurrence of urinary tract infections encourages exposure to antibiotics, so prevention is of vital importance. Prevention based on treatments other than antibiotics (non-antibiotic prophylaxis) is of the greatest interest, not only to prevent UTIs, but also to reduce exposure to antibiotics and the ecological pressure they exert. However, few strategies are available, and very few have been well evaluated in high-risk populations.\n\nBacterial lysates such as Escherichia Coli extract (OM-89), an immunoactive prophylaxis, are an original and innovative strategy that has been developed for the prevention of recurrent UTIs, and could constitute a therapeutic option in particularly at-risk populations.\n\nIn vivo studies have shown that OM-89 :\n\n* increases IgA levels in intestinal secretions and in the urine of mice (Bosh AV Immunopharmacol Immunotoxicol 1988; Baier W Arzneim Forsch Drug Res 1997),\n* stimulates the production of serum IgG and IgA recognising a number of bacteria isolated from patients with urinary tract infections and enterohaemorrhagic E. coli infections (Huber M, Int J immunopharmacol 2000),\n* stimulates the killing capacity of rabbit polymorphonuclear leukocytes against E. coli and S. aureus (Nauck M, Int J Exp Clin Chemother 1991),\n* protects against acute infection with E. coli or P. aeruginosa,\n* and inhibits inflammation associated with lipopolysaccharide-induced cystitis in mice (Lee SJ, World J Urol 2006).\n\nClinically, certain studies in patients with recurrent UTIs have shown a significant reduction in the number of urinary tract infections with OM-89 compared to placebo or an antibiotic (Bauer Eur Urol 2005; Naber KG Int J Antimicrob Agents 2009; Wade DT, Clin Rehabil 2020).\n\nHowever, these promising results suffer from methodological limitations and need to be confirmed by a high-quality trial carried out on a sample appropriate to the research question and in a homogeneous patient population.\n\nPatients with spinal cord injuries are a population at high risk of recurrent UTIs, and prevention is a major issue, given the incidence of MRBs in this population. It is therefore important in this high-risk population not only to rigorously evaluate the efficacy of OM-89 in reducing antibiotic consumption for UTIs, but also to assess its impact on bacterial resistance and on the microbiota (urinary and digestive). These patients could therefore see significant benefits: less frequent urinary tract infections and reduced antibiotic use. In addition, this population could serve as a model for other populations with or without neurological impairment suffering from recurrent UTIs",[27],"2026-03-16",{"date":207,"type":36},"2026-03-17",{"date":209,"type":36},"2024-12-16",{"date":211,"type":20},"2028-12",{"name":213,"class":72},"Centre Hospitalier Universitaire Dijon",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":223,"phases":4,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":44},"100622974","patient-and-caregiver-perspectives-on-intravesical-instillations-for-urinary-symptoms-100622974","NCT07390591","Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms","Intravesical Gentamicin Coupled With Lactobacillus Rhamnosus for Urinary Health- Early Career","Inclusion Criteria:\n\nCriteria for patients:\n\n* Age 18+\n* Diagnosis of NLUTD\n* Chronic catheter usage (minimum 6 months), either intermittent catheterization or indwelling catheter\n* Community-dwelling\n* Experience using intravesical Lactobacillus, gentamicin, or combination of the two\n\nCriteria for caregivers:\n\n* Age 18+\n* Care for patient with diagnosis of NLUTD\n* Care for patient who has used catheters chronically (minimum 6 months)\n* Experience facilitating patients' use of intravesical Lactobacillus, gentamicin, or combination of the two\n\nExclusion Criteria:\n\n* Psychiatric or psychologic conditions impacting ability to consent",{"count":222,"type":20},60,"OBSERVATIONAL","The goal of this observational qualitative study is to learn about the experiences and perspectives of patients with neurogenic lower urinary tract dysfunction (NLUTD) and their caregivers regarding different types of intravesical instillations used for urinary health. The study aims to understand the perceived benefits, challenges, and opportunities related to Lactobacillus-only, gentamicin-only, and combined gentamicin-Lactobacillus instillations. The main question this study seeks to answer is:\n\n1\\. Determine patient and caregivers' preferences, and overall experiences regarding intravesical therapeutics for urinary symptoms and UTI\n\nResearchers will compare responses from four groups: participants who have used Lactobacillus-only instillations, gentamicin-only instillations, combined gentamicin-Lactobacillus instillations, and caregivers who have experience supporting instillations.\n\nParticipants will take part in a one-hour semi-structured interview and may be contacted for brief follow-up discussions to clarify findings. Interviews will be audio-recorded, transcribed, and analyzed using qualitative data software to identify themes related to treatment preferences and acceptability.",[226,227,27],"Spinal Cord Injuries","Neurogenic Lower Urinary Tract Dysfunction","2026-01-28",{"date":230,"type":36},"2026-02-05",{"date":232,"type":36},"2025-06-19",{"date":234,"type":20},"2027-09",{"name":236,"class":72},"Medstar Health Research Institute",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":171,"minAge":17,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":21,"phases":246,"briefSummary":248,"conditions":249,"keywords":258,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":137},"100622722","phase-4-a-randomized-placebo-controlled-trial-of-nitrous-oxide-during-in-office-bladder-botox-injections-100622722","NCT07387315","A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections","A Randomized, Placebo Controlled Trial of Nitrous Oxide\u002FOxygen Plus Standard Care Versus Standard Care Alone During In-office Intradetrusor onabotulinumtoxinA (Botox) Injections","Inclusion Criteria:\n\n* Adult women ≥18 years old scheduled for in-office intradetrusor botulinum toxin injection and able to consent.\n\nExclusion Criteria:\n\n* Known\u002Fsuspected vitamin B12 or folate deficiency or high-risk state (e.g., pernicious anemia, malabsorption, post-bariatric or strict vegan without supplementation)\n* currently pregnant\n* severe\u002Funstable pulmonary disease or baseline hypoxemia requiring supplemental home oxygen\n* eye or ear surgery in the last six weeks\n* trapped-air conditions (e.g., untreated pneumothorax, bowel obstruction)\n* severe active otitis\u002Fsinus disease\n* inability to follow directions\n* history of adverse reaction to nitrous oxide",{"count":245,"type":20},96,[247],"PHASE4","The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections. The primary question it aims to answer is: Does using nitrous oxide lower the overall level of pain during the procedure?\n\nResearchers will compare a 50:50 nitrous oxide\u002Foxygen mixture (administered with the Pro-Nox system) plus standard care (with lidocaine in the bladder) to sham mask plus standard care to see if nitrous oxide works better for lowering pain.\n\nParticipants will:\n\n* Receive their bladder Botox injection in the office setting\n* Either use nitrous oxide\u002Foxygen plus standard care during the procedure, or sham mask plus standard care\n* Answer brief questions about pain, anxiety, satisfaction, and willingness to repeat the procedure",[177,27,250,251,252,253,254,255,256,257],"Urge Incontinence","Pain","Urinary Incontinence","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Bladder Neurogenesis","Urinary Incontinence, Urge","Pelvic Floor Disorders",[177,252,250,259,260,90,261,262,263,264,265,266,267,268],"Intradetrusor Injection","OnabotulinumtoxinA","Bladder Botox","Botulinum Toxins, Type A","Pain Management","Analgesia","Nitrous Oxide","Office-based Procedures","Urogynecology","Pelvic Floor Disorder",{"date":270,"type":36},"2026-02-04",{"date":272,"type":20},"2026-02",{"date":274,"type":20},"2026-12",{"name":276,"class":72},"TriHealth Inc.",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":44},"100616684","early-phase-1-intravesical-lactobacillus-crispatus-clinical-safety-and-microbiome-evaluation-100616684","NCT07308808","Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation","Inclusion Criteria:\n\n* Age ≥ 18 years\n* SCI with at least 6-month duration\n* NLUTD\n* Utilizing intermittent catheterization for bladder management\n* Community dwelling\n\nExclusion Criteria:\n\n* Use of prophylactic antibiotics\n* Instillation of intravesical antimicrobials to prevent UTI\n* Psychological or psychiatric conditions influencing the ability to follow instructions\n* Use of oral or IV antibiotics in the past 2 weeks\n* Pregnancy\n* Known genitourinary pathology beyond NLUTD\n* Participation in another study that could confound results of the proposed study",{"count":284,"type":20},40,[111],"The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\\[s\\] it aims to answer are:\n\n1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC).\n2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC).\n\nIf there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome.\n\nParticipants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.",[288,27,289],"Spinal Cord Injuries (SCI)","Urinary Tract Infection (Diagnosis)","2025-12-22",{"date":292,"type":36},"2025-12-30",{"date":294,"type":36},"2025-09-09",{"date":296,"type":20},"2027-03-30",{"name":236,"class":72},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":309,"conditions":310,"keywords":317,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":331},"100495100","phase-3-the-role-of-preoperative-immunonutrition-on-morbidity-and-immune-response-after-cystectomy-incyst-trial-100495100","NCT05726786","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial)","INCyst","Inclusion Criteria:\n\n* Patient undergoing open cystectomy (for all reasons)\n* Age ≥18 years\n* Ability and willingness to provide informed consent documented by signature\n\nExclusion Criteria:\n\n* Contraindications to IN, e.g. known hypersensitivity or allergy to lactose, fish oil or soy lecithin\n* Severe diarrhoea requiring medical attention\n* Current treatment with any immunosuppressive drug\n* In standard practice, pregnant or lactating women are systematically rejected by the surgeon for this surgical procedure. Furthermore, during the pre-surgical anaesthesia consultation, the eligibility of each patient for anaesthesia will be assessed according to the usual criteria and recommendations of the anaesthesia service of the CHUV\n* Other clinically significant concomitant disease affecting immunity (e.g., severe renal failure, HIV, SLE, transplant recipient, ...)\n* Inability to follow the procedures of the study, e.g. due psychological disorders, dementia, etc.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Use of IN independently of the study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n* Emergency procedure (less than 7 days between screening and surgery)",{"count":307,"type":20},232,[202],"The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy.\n\nAs a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN.\n\nThis is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.",[311,312,313,27,314,315,316],"Bladder Cancer","Interstitial Cystitis","Painful Bladder Syndrome","Hemorrhagic Cystitis","Endometriosis","Bladder Disease",[318,319,320,321],"Cystectomy","Immunonutrition","Complication","Malnutrition","2025-12-02",{"date":324,"type":36},"2025-12-09",{"date":326,"type":36},"2023-04-10",{"date":328,"type":20},"2026-10",{"name":330,"class":72},"Centre Hospitalier Universitaire Vaudois",4,{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":21,"phases":340,"briefSummary":341,"conditions":342,"keywords":343,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":44},"100387361","phase-2-intravesical-lactobacillus-for-urinary-symptoms-among-people-with-nlutd-who-use-indwelling-catheters-100387361","NCT04323735","Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters","Inclusion Criteria:\n\n* Neurogenic bladder for at least 6 months;\n* Utilizing indwelling catheterization for bladder management;\n* Women must be premenopausal and not currently menstruating;\n* Community dwelling\n* physical disability\n\nExclusion Criteria:\n\n* Use of prophylactic antibiotics;\n* Instillation of intravesical antimicrobials to prevent UTI;\n* Psychologic or psychiatric conditions influencing the ability to follow instructions;\n* Use of oral or IV antibiotics within the past 2 weeks;\n* Sexual activity within the previous 72 hours;\n* Participation in another study with which results could be confounded.",{"count":339,"type":20},182,[24],"The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.",[27],[344,345,346],"Indwelling catheter","Foley catheter","Suprapubic Catheter","2025-10-20",{"date":349,"type":36},"2025-10-22",{"date":351,"type":36},"2020-01-10",{"date":353,"type":20},"2026-09",{"name":236,"class":72},{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":21,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":44},"100456970","phase-2-intravesical-lgg-vs-saline-bladder-wash-rct-100456970","NCT05230511","Intravesical LGG VS Saline Bladder Wash RCT","Intravesical Lactobacillus rhamnosusGG Versus Saline Bladder Wash: A Randomized, Controlled, Comparative Effectiveness Clinical Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. SCI at least 6 months duration;\n3. NLUTD (as determined by their SCI physician or urologist);\n4. Utilizing intermittent catheterization for bladder management; and\n5. Community dwelling (discharged from the acute care setting).\n\nExclusion Criteria:\n\n1. Known genitourinary pathology beyond neuropathic bladder (i.e., vesicoureteral reflux, bladder or kidney stones, etc.);\n2. Use of prophylactic antibiotics;\n3. Instillation of intravesical agents (e.g., gentamycin, saline; or Lactobacillus);\n4. Immunodeficiency;\n5. Any oral antibiotics within the past 2 weeks;\n6. Psychologic or psychiatric conditions influencing the ability to follow instructions;\n7. Participation in another study in which results would be confounded;\n8. 6 months since prior exposure to intravesical LGG®; and\n9. Active cancer (or within 5 years) or active autoimmune disorder",{"count":363,"type":20},120,[24],"This is the first ever comparative effectiveness study of an antibiotic-sparing novel self-management intervention to prevent complicated urinary tract infection (UTI).",[226,27],[368],"Intermittent Catheter","2025-08-25",{"date":371,"type":36},"2025-08-29",{"date":373,"type":36},"2022-06-13",{"date":375,"type":20},"2026-12-31",{"name":236,"class":72},{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":384,"sex":52,"minAge":17,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":223,"phases":4,"briefSummary":388,"conditions":389,"keywords":391,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":44},"100155269","lower-urinary-tract-dysfunction-database-100155269","NCT01293110","Lower Urinary Tract Dysfunction Database","Database of Patients With Lower Urinary Tract Dysfunction Treated at the University of Zürich","Inclusion Criteria:\n\n* patient of Balgrist University Hospital\n* patient of University Hospital Zürich\n* urodynamic examination\n* written informed consent\n\nExclusion Criteria:\n\n* no written informed consent",true,"90 Years",{"count":387,"type":20},7000,"Patients with neurological disease\u002Finjury often suffer from lower urinary tract symptoms, which frequently have a negative impact on the patients' health related quality of life. The prevalence of lower urinary tract dysfunction is high and the treatment is a challenge because available treatments may fail. In this study data of patients with lower urinary tract dysfunction treated at the University of Zürich, are prospectively and systematically collected in a database.",[27,390],"Diseases of the Lower Urinary Tract: General Conditions",[392,393,394],"urodynamics","neurogenic lower urinary tract dysfunction","neurological disease\u002Finjury","2025-03-29",{"date":397,"type":36},"2025-04-03",{"date":399,"type":4},"2010-01",{"date":401,"type":20},"2030-01",{"name":403,"class":72},"University of Zurich",{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":21,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":44},"100555679","improving-pelvic-rehabilitation-using-epidural-stimulation-after-spinal-cord-injury-100555679","NCT06515223","Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury","ImPRESS","Inclusion Criteria:\n\n* Spinal Cord Injury (supra-sacral)\n* AIS A-D\n* \\>18 years;\n* SCI sustained \\>12 months ago;\n* Neurogenic detrusor overactivity (NDO) confirmed on urodynamics;\n* Responsive to dorsal genital nerve stimulation\n* Willing and able to provide informed consent\n* Stable medical, physical and psychological condition as considered by the investigators\n* Able to understand and interact with the study team in English\n* Sufficient upper limb function to operate the device\n* Suitably optimised bladder and bowel routine\n\nExclusion Criteria:\n\n* Transected cord or SCI related to a neurodegenerative disease\n* Any device or metal work in situ that would exclude the patient from having eSCS implanted\n* Intra-detrusor botulinum toxin injections within the last 6 months\n* Previous surgical intervention on bladder sphincters\n* Any diseases and conditions that would exclude the patient from eSCS and\u002For surgery, for example, degenerative spinal pathology, syrinx and\u002For tumor.\n* Recurrent urinary tract infection refractory to antibiotics\n* Women who are pregnant or intending to become pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding, or lack of safe contraception for women of childbearing capacity.\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the participant\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons.",{"count":412,"type":20},20,[56],"The investigators will recruit up to 20 volunteers with chronic, supra-sacral SCI. Following screening, eligible participants will enter 'Phase I', they will complete baseline outcome measures and then have the epidural spinal cord stimulator (eSCS) implanted with either percutaneous or paddle electrodes. Preoperative and intraoperative testing will determine exact location of electrodes.\n\nMapping and optimisation of stimulation parameters will be performed simultaneously with urodynamic investigations of bladder function, and anorectal physiology investigations of bowel function. The acute effects of eSCS to suppress bladder overactivity, facilitate voiding, prevent unwanted reflex sphincter activity, and pelvic floor function will guide development of eSCS programmes for use at home.\n\nIn 'Phase II', participants will use eSCS at home for 12-weeks. Participants will also be taught how to perform bladder and pelvic floor muscle training (PFMT) in combination with eSCS.\n\nOutcome measures assessing bladder, bowel, sexual function, quality of life, motor function and spasticity will be captured prior to and following the 12-week intervention, and at 3 and 6 month follow up.",[226,182,27,416,417],"Neurogenic Bowel","Neurogenic Detrusor Overactivity","2025-03-13",{"date":420,"type":36},"2025-03-14",{"date":422,"type":36},"2024-10-14",{"date":424,"type":20},"2027-11-01",{"name":426,"class":72},"University College, London",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":171,"minAge":17,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":436,"briefSummary":437,"conditions":438,"keywords":442,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":44},"100569541","phase-4-optimal-intravesical-lidocaine-volume-for-pain-relief-during-office-intra-detrusor-onabotulinum-toxin-a-injections-100569541","NCT06695585","Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections","Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections: a Prospective Randomized Superiority Trial","Inclusion Criteria:\n\n* Adult female, \\>18 years, English-speaking (surveys utilized are not validated in all languages)\n* Able to provide informed consent\n* Indications: Refractory urge urinary incontinence, Refractory urinary urgency and frequency, Neurogenic bladder (without sensory deficit)\n\nExclusion Criteria:\n\n* Untreated urinary tract infection at the time of procedure\n* Contra-indication to Botox\n* Contraindication to intravesical lidocaine\n* Inability to provide informed consent\n* Pregnancy, breast-feeding, intending to become pregnant within 6 months of treatment",{"count":435,"type":20},36,[247],"The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.",[177,439,440,441,250,27],"Overactive Bladder Syndrome","Urinary Urgency","Urinary Frequency",[261,443,444],"Intravesical lidocaine","office Botox","2024-11-15",{"date":447,"type":36},"2024-11-19",{"date":449,"type":20},"2024-12-01",{"date":451,"type":20},"2025-12-01",{"name":453,"class":72},"University of Louisville"]